Efficacy and safety of ceritinib in anaplastic lymphoma kinase‐rearranged non‐small cell lung cancer: A systematic review and meta‐analysis

WHAT IS KNOWN AND OBJECTIVE: Ceritinib is a new, oral, potent and selective second‐generation anaplastic lymphoma kinase (ALK) inhibitor approved by the Food and Drug Administration of the United States in April 2014. It is active in crizotinib‐resistant patients, especially in patients with non‐sma...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Wei, Zhang, Ping, Yuan, Yuan, Deng, Xiao‐Hui, Yue, Rui, Ge, Xiao‐Zhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384129/
https://www.ncbi.nlm.nih.gov/pubmed/32369239
http://dx.doi.org/10.1111/jcpt.13157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384129/
https://www.ncbi.nlm.nih.gov/pubmed/32369239
http://dx.doi.org/10.1111/jcpt.13157

Ejemplares similares